User menu

Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?

Bibliographic reference Walrand, Stephan ; Flux, Glenn D ; Konijnenberg, Mark W ; Valkema, Roelf ; Krenning, Eric P ; et. al. Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, no. Suppl. 1, p. S57-568 (2011)
Permanent URL
  1. Brans Boudewijn, Linden Ola, Giammarile Francesco, Tennvall Jan, Punt Cornelis, Clinical applications of newer radionuclide therapies, 10.1016/j.ejca.2005.12.020
  2. de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:13S–7S.
  3. Mahé Marc André, Lisbona Albert, Chatal Jean-François, Therapeutic nuclear medicine expands to breast cancer, 10.1007/s00259-009-1319-2
  4. Flux Glenn D., Haq Masud, Chittenden Sarah J., Buckley Susan, Hindorf Cecilia, Newbold Kate, Harmer Clive L., A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer, 10.1007/s00259-009-1261-3
  5. Campbell Janice M., Wong C. Oliver, Muzik Otto, Marples Brian, Joiner Michael, Burmeister Jay, Early Dose Response to Yttrium-90 Microsphere Treatment of Metastatic Liver Cancer by a Patient-Specific Method Using Single Photon Emission Computed Tomography and Positron Emission Tomography, 10.1016/j.ijrobp.2008.12.058
  6. Flamen Patrick, Vanderlinden Bruno, Delatte Philippe, Ghanem Ghanem, Ameye Lieveke, Eynde Marc Van Den, Hendlisz Alain, Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres, 10.1088/0031-9155/53/22/019
  7. Wessels B. W., Konijnenberg M. W., Dale R. G., Breitz H. B., Cremonesi M., Meredith R. F., Green A. J., Bouchet L. G., Brill A. B., Bolch W. E., Sgouros G., Thomas S. R., MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy, 10.2967/jnumed.108.053173
  8. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47(9):1467–75.
  9. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46:92S–8S.
  10. Walrand S, Barone R, Pauwels S, Jamar F. Experimental facts supporting a red marrow uptake due to radiometal transchelation in (90)Y-DOTATOC therapy and relationship to the decrease of platelet counts. Eur J Nucl Med Mol Imaging 2011. doi: 10.1007/s00259-011-1744-x .
  11. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S–106S.
  12. Bodei Lisa, Cremonesi Marta, Grana Chiara, Rocca Paola, Bartolomei Mirco, Chinol Marco, Paganelli Giovanni, Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours, 10.1007/s00259-004-1571-4
  13. Barendsen G.W., Broerse J.J., Experimental radiotherapy of a rat rhabdomyosarcoma with 15 MeV neutrons and 300 kV X-rays, 10.1016/0014-2964(70)90006-x
  14. Wahl R. L., Jacene H., Kasamon Y., Lodge M. A., From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, 10.2967/jnumed.108.057307
  15. Curtis S.B., Barendsen G.W., Hermens A.F., Cell kinetic model of tumour growth and regression for a rhabdomyosarcoma in the rat: Undisturbed growth and radiation response to large single doses, 10.1016/0014-2964(73)90076-5
  16. Connell P. P., Hellman S., Advances in Radiotherapy and Implications for the Next Century: A Historical Perspective, 10.1158/0008-5472.can-07-6871
  18. Walrand Stéphan, Jamar François, Mathieu Isabelle, Camps Joëlle, Lonneux Max, Sibomana Mérence, Labar Daniel, Michel Christian, Pauwels Stanislas, Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86, 10.1007/s00259-002-1068-y
  19. Pentlow K, Quantitative Imaging of Yttrium-86 with PET The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions, 10.1016/s1095-0397(00)00046-7
  20. Buchholz H. G., Herzog H., Förster G. J., Reber H., Nickel O., Rösch F., Bartenstein P., PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction, 10.1007/s00259-002-1112-y
  21. Herzog H, Tellmann L, Scholten B, Coenen HH, Qaim SM. PET imaging problems with the non-standard positron emitters yttrium-86 and iodine-124. Q J Nucl Med Mol Imaging 2008;52(2):159–65.
  22. Kull Thomas, Ruckgaber Jochen, Weller Rolf, Reske Sven, Glatting Gerhard, Quantitative Imaging Of Yttrium-86 Pet with the Ecat Exact Hr+In 2D Mode, 10.1089/cbr.2004.19.482
  23. Barker W.C., Szajek L.P., Green S.L., Carson R.E., Improved quantification for Tc-94m PET imaging, 10.1109/23.940156
  24. Beattie Bradley J., Finn Ronald D., Rowland Douglas J., Pentlow Keith S., Quantitative imaging of bromine-76 and yttrium-86 with PET: A method for the removal of spurious activity introduced by cascade gamma rays, 10.1118/1.1595599
  25. Vandenberghe Stefaan, Three-dimensional positron emission tomography imaging with 124I and 86Y : , 10.1097/01.mnm.0000199476.46525.2c
  26. Palm S, Enmon RM, Matei C, Kolbert KS, Xu S, Zanzonico PB, et al. Pharmacokinetics and biodistribution of (86)Y-trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative microPET and MRI. J Nucl Med 2003;44(7):1148–55.
  27. Nayak T. K., Garmestani K., Baidoo K. E., Milenic D. E., Brechbiel M. W., Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma, 10.2967/jnumed.109.071290
  28. McDevitt Michael R., Chattopadhyay Debjit, Jaggi Jaspreet S., Finn Ronald D., Zanzonico Pat B., Villa Carlos, Rey Diego, Mendenhall Juana, Batt Carl A., Njardarson Jon T., Scheinberg David A., PET Imaging of Soluble Yttrium-86-Labeled Carbon Nanotubes in Mice, 10.1371/journal.pone.0000907
  29. Clifford Thomas, Boswell C. Andrew, Biddlecombe Gráinne B., Lewis Jason S., Brechbiel Martin W., Validation of a Novel CHX-A‘ ‘ Derivative Suitable for Peptide Conjugation:  Small Animal PET/CT Imaging Using Yttrium-86-CHX-A‘ ‘-Octreotide, 10.1021/jm060317v
  30. Nayak Tapan K., Regino Celeste A. S., Wong Karen J., Milenic Diane E., Garmestani Kayhan, Baidoo Kwamena E., Szajek Lawrence P., Brechbiel Martin W., PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab, 10.1007/s00259-009-1370-z
  31. Schlesinger Joern, Koezle Inge, Bergmann Ralf, Tamburini Sergio, Bolzati Cristina, Tisato Francesco, Noll Bernhard, Klussmann Sven, Vonhoff Stefan, Wuest Frank, Pietzsch Hans-Juergen, Steinbach Joerg, An86Y-Labeled Mirror-Image Oligonucleotide: Influence of Y-DOTA Isomers on the Biodistribution in Rats†, 10.1021/bc700453h
  32. Nayak Tapan K., Garmestani Kayhan, Baidoo Kwamena E., Milenic Diane E., Brechbiel Martin W., PET imaging of tumor angiogenesis in mice with VEGF-A-targeted 86Y-CHX-A″-DTPA-bevacizumab, 10.1002/ijc.25409
  33. Xu Heng, Baidoo Kwamena E., Wong Karen J., Brechbiel Martin W., A novel bifunctional maleimido CHX-A″ chelator for conjugation to thiol-containing biomolecules, 10.1016/j.bmcl.2008.03.022
  34. Kutzner J, Hahn K, Beyer GJ, Grimm W, Bockisch A, Rösler HP. Scintigraphic use of 87Y during 90Y therapy of bone metastases. Nuklearmedizin 1992;31(2):53–6.
  35. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin’s lymphoma. J Nucl Med 2003;44(1):77–84.
  36. Postema Ernst J., Frielink Cathelijne, Oyen Wim J.G., Raemaekers John M.M., Goldenberg David M., Corstens Frans H.M., Boerman Otto C., Biodistribution of131I-,186Re-,177Lu-, and88Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive Lymphoma, 10.1089/108497803322287592
  37. Goodwin DA, Meares CF, Watanabe N, McTigue M, Chaovapong W, Ransone CM, et al. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy. Cancer Res 1994;54(22):5937–46.
  38. Buchsbaum D.J., Hanna D.E., Randall B.C., Buchegger F., Mach J.-P., Radiolabeling of monoclonal antibody against carcinoembryonic antigen with 88Y and biodistribution studies, 10.1016/0047-0740(85)90160-3
  39. Kutzner J, Mittas M, Grimm W. Distribution in rats after intravenous injection of 88Y compounds. Nuklearmedizin 1981;20(1):35–9.
  40. Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ, et al. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med 2004;45(7):1224–32.
  41. Moi MK, DeNardo SJ, Meares CF. Stable bifunctional chelates of metals used in radiotherapy. Cancer Res 1990;50(3 Suppl):789s–93s.
  42. Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans RP, Gansow OA, et al. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res 1989;49(10):2639–44.
  43. Deshpande SV, DeNardo SJ, Kukis DL, Moi MK, McCall MJ, DeNardo GL, et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31(4):473–9.
  44. Beyer G.J., Bergmann R., Kampf G., Mäding P., Rösch F., Simultaneous study of the biodistribution of radio-yttrium complexed with EDTMP and citrate ligands in tumour-bearing rats, 10.1016/0883-2897(92)90008-m
  45. Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989;30(5):672–82.
  46. Kobayashi Hisataka, Wu Chuanchu, Kim Meyoung-Kon, Paik Chang H., Carrasquillo Jorge A., Brechbiel Martin W., Evaluation of the in Vivo Biodistribution of Indium-111 and Yttrium-88 Labeled Dendrimer-1B4M-DTPA and Its Conjugation with Anti-Tac Monoclonal Antibody†, 10.1021/bc980091d
  47. Goodwin DA, Meares CF, Osen M. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J Nucl Med 1998;39(10):1813–8.
  48. Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, et al. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters. Clin Cancer Res 1999;5(10 Suppl):3031s–43s.
  49. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55(17):3825–34.
  50. Camera Luigi, Kinuya Seigo, Garmestani Kayhan, Brechbiel Martin W., Wu Chuanchu, Pai Lee H., McMurry Thomas J., Gansow Otto A., Pastan Ira, Paik Chang H., Carrasquillo Jorge A., Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA), 10.1007/bf00285586
  51. Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, Snow GB, et al. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003;44(10):1663–70.
  52. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46(11):1898–906.
  53. Verel Iris, Visser Gerard W.M., Boerman Otto C., van Eerd Julliette E.M., Finn Ron, Boellaard Ronald, Vosjan Maria J.W.D., Stigter-van Walsum Marijke, Snow Gordon B., van Dongen Guus E.M., Long-Lived Positron Emitters Zirconium-89 and Iodine-124 for Scouting of Therapeutic Radioimmunoconjugates with PET, 10.1089/108497803322287745
  54. Perk Lars R., Visser Otto J., Stigter-van Walsum M., Vosjan Maria J. W. D., Visser Gerard W. M., Zijlstra Josée M., Huijgens Peter C., van Dongen Guus A. M. S., Preparation and evaluation of 89Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron emission tomography, 10.1007/s00259-006-0160-0
  55. Bailey M.R., Fry F.A., James A.C., Long-term retention of particles in the human respiratory tract, 10.1016/0021-8502(85)90037-0
  56. Ford Kenneth W., Predicted 0+ Level inZr9040, 10.1103/physrev.98.1516
  57. Nickles R.J., Roberts A.D., Nye J.A., Converse A.K., Barnhart T.E., Avila-Rodriguez M.A., Sundaresan R., Dick D.W., Hammas R.J., Thomadsen B.R., Assaying and PET Imaging of Ytrrium-90: 1<<34ppm<0, 10.1109/nssmic.2004.1466619
  58. Selwyn R.G., Nickles R.J., Thomadsen B.R., DeWerd L.A., Micka J.A., A new internal pair production branching ratio of 90Y: The development of a non-destructive assay for 90Y and 90Sr, 10.1016/j.apradiso.2006.08.009
  59. Langhoff H, Hennies H. Zum experimentellen Nachweis von Zweiquantenzerfall beim 0+-0+-Übergang des Zr90. Z Angew Phys 1961;164:166–73.
  60. Lhommel Renaud, Goffette Pierre, Van den Eynde Marc, Jamar François, Pauwels Stanislas, Bilbao Jose I., Walrand Stephan, Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT, 10.1007/s00259-009-1210-1
  61. Werner Matthias K., Brechtel Klaus, Beyer Thomas, Dittmann Helmut, Pfannenberg Christina, Kupferschläger Jürgen, PET/CT for the assessment and quantification of 90Y biodistribution after selective internal radiotherapy (SIRT) of liver metastases, 10.1007/s00259-009-1317-4
  62. Rault E, Clementel E, Vandenberghe S, D’Asseler Y, Van Holen R, De Beenhouwer J, et al. Comparison of yttrium-90 SPECT and PET images. J Nucl Med 2010;51(2):125S.
  63. Lhommel Renaud, van Elmbt Larry, Goffette Pierre, Van den Eynde Marc, Jamar François, Pauwels Stanislas, Walrand Stephan, Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres, 10.1007/s00259-010-1470-9
  64. Gates V. L., Esmail A. A. H., Marshall K., Spies S., Salem R., Internal Pair Production of 90Y Permits Hepatic Localization of Microspheres Using Routine PET: Proof of Concept, 10.2967/jnumed.110.080986
  65. Walrand S., Jamar F., van Elmbt L., Lhommel R., Bekonde E. B., Pauwels S., 4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90Y PET, 10.2967/jnumed.110.080093
  66. Ito Shigeki, Kurosawa Hiroyuki, Kasahara Hiroyuki, Teraoka Satomi, Ariga Eiji, Deji Shizuhiko, Hirota Masahiro, Saze Takuya, Minamizawa Takao, Nishizawa Kunihide, 90Y bremsstrahlung emission computed tomography using gamma cameras, 10.1007/s12149-009-0233-9
  67. Shen S, DeNardo GL, Yuan A, DeNardo DA, DeNardo SJ. Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med 1994;35(8):1381–9.
  68. Shen Sui, DeNardo Gerald L., DeNardo Sally J., Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter, 10.1118/1.597198
  69. Qian Wei, Clarke Laurence P., A restoration algorithm for P-32 and Y-90 bremsstrahlung emission nuclear imaging: A wavelet-neural network approach, 10.1118/1.597868
  70. Siegel JA. Quantitative bremsstrahlung SPECT imaging: attenuation-corrected activity determination. J Nucl Med 1994;35(7):1213–6.
  71. Clarke LP, Cullom SJ, Shaw R, Reece C, Penney BC, King MA, et al. Bremsstrahlung imaging using the gamma camera: factors affecting attenuation. J Nucl Med 1992;33(1):161–6.
  72. Kappadath SC, SU-GG-I-163: A Scatter Correction Algorithm for Quantitative Yttrium-90 SPECT Imaging, 10.1118/1.3468199
  73. Kallergi M, Abernathy MJ, Li HD. Yttrium-90 attenuation measurements before and after maximum entropy image restoration. J Nucl Med 1994;35(5):161S.
  74. Heard S., Flux G.D., Guy M.J., Ott R.J., Monte Carlo Simulation of /sup 90/Y Bremsstrahlung Imaging, 10.1109/nssmic.2004.1466658
  75. Minarik D, Sjögreen Gleisner K, Ljungberg M, Evaluation of quantitative90Y SPECT based on experimental phantom studies, 10.1088/0031-9155/53/20/008
  76. Ljungberg Michael, Frey Eric, Sjögreen Katarina, Liu Xiaowei, Dewaraja Yuni, Strand Sven-Erik, 3D Absorbed Dose Calculations Based on SPECT: Evaluation for 111-In/90-Y Therapy using Monte Carlo Simulations, 10.1089/108497803321269377
  77. Rault E, Vandenberghe S, Staelens S, Van Holen R, Lemahieu I. Optimization of Y90 bremsstrahlung image reconstruction using multiple energy window subsets. J Nucl Med 2008;49(1):399P.
  78. Rault E., Vandenberghe S., Staelens S., Lemahieu I., Optimization of Yttrium-90 Bremsstrahlung Imaging with Monte Carlo Simulations, IFMBE Proceedings (2009) ISBN:9783540892076 p.500-504, 10.1007/978-3-540-89208-3_119
  79. Fabbri Cinzia, Sarti Graziella, Cremonesi Marta, Ferrari Mahila, Dia Amalia Di, Agostini Monica, Botta Francesca, Paganelli Giovanni, Quantitative Analysis of90Y Bremsstrahlung SPECT-CT Images for Application to 3D Patient-Specific Dosimetry, 10.1089/cbr.2008.0543
  80. Minarik D, Ljungberg M, Segars P, Gleisner K Sjögreen, Evaluation of quantitative planar90Y bremsstrahlung whole-body imaging, 10.1088/0031-9155/54/19/014
  81. Flux Glenn D, Guy Matthew J, Beddows Ruth, Pryor Matthew, Flower Maggie A, Estimation and implications of random errors in whole-body dosimetry for targeted radionuclide therapy, 10.1088/0031-9155/47/17/311
  82. Herzog H, Rösch F, Stöcklin G, Lueders C, Qaim SM, Feinendegen LE. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 1993;34(12):2222–6.
  83. R�sch Frank, Herzog Hans, Plag Cornelius, Neumaier Bernd, Braun Ulrike, M�ller-G�rtnere Hans-Willhelm, St�cklin Gerhard, Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography, 10.1007/bf01084371
  84. Sgouros George, Yttrium-90 biodistribution by yttrium-87 imaging: A theoretical feasibility analysis, 10.1118/1.598323
  85. Ismail A., Giraud J.-Y., Lu G.N., Sihanath R., Pittet P., Galvan J.M., Balosso J., Radiotherapy quality insurance by individualized in vivo dosimetry: State of the art, 10.1016/j.canrad.2009.01.001
  86. Smith T, Shawe D J, Crawley J C, Gumpel J M, Use of single photon emission computed tomography (SPECT) to study the distribution of 90Y in patients with Baker's cysts and persistent synovitis of the knee., 10.1136/ard.47.7.553
  87. Smith T., Crawley J. C. W., Shawe D. J., Gumpel J. M., SPECT using Bremsstrahlung to quantify 90Y uptake in Baker's cysts: Its application in radiation synovectomy of the knee, 10.1007/bf00252396
  88. Rhymer S, Parker JA, Palmer M. Detection of Y-90 extravasation by bremsstrahlung imaging for patients undergoing yttrium-90-ibritumomab tiuxetan (Zevalin) therapy. J Nucl Med 2008;49(1):417P.
  89. Sebastian A. J., Szyszko T., Al-Nahhas A., Nijran K., Tait N. P., Evaluation of Hepatic Angiography Procedures and Bremsstrahlung Imaging in Selective Internal Radiation Therapy: A Two-Year Single-Center Experience, 10.1007/s00270-008-9298-4
  90. Mansberg Robert, Sorensen Nicole, Mansberg Victor, Van der Wall Hans, Yttrium 90 Bremsstrahlung SPECT/CT scan demonstrating areas of tracer/tumour uptake, 10.1007/s00259-007-0536-9
  91. Machac J, Weintraub J, Nowakowski F, Mobley D, Zhang Z, Warner R. Variations in liver perfusion patterns in patients with liver tumors undergoing therapy with yttrium-90 microspheres, studied with SPECT/CT. J Nucl Med 2007;48(2):396P.
  92. Knesaurek K, Muzinic M, Zhang Z, DaCosta M, Machac J. Comparison of visual and computer calculated coregistration of Y-90 and Tc-99m MAA SPECT/CT images in treatment of liver cancer. J Nucl Med 2008;49(1):112P.
  93. Knešaurek Karin, Machac Josef, Muzinic Michael, DaCosta Maria, Zhang Zhuangyu, Heiba Sherif, Quantitative Comparison of Yttrium-90 (90 Y)-Microspheres and Technetium-99m (99m Tc)-Macroaggregated Albumin SPECT Images for Planning 90 Y Therapy of Liver Cancer, 10.1177/153303461000900304
  94. Moore S, Park M, Mueller S. Activity estimation performance in Y-90 microsphere bremsstrahlung SPECT. J Nucl Med 2009;50(2):1433.
  95. Tehranipour Neda, AL-Nahhas Adil, Canelo Ruben, Stamp Gordon, Woo Karen, Tait Paul, Gishen Philip, Concordant F-18 FDG PET and Y-90 Bremsstrahlung Scans Depict Selective Delivery of Y-90-Microspheres to Liver Tumors: Confirmation With Histopathology : , 10.1097/
  96. Simon Norman, Feitelberg Sergei, Scanning Bremsstrahlung of Yttrium-90 Microspheres Injected Intra-arterially, 10.1148/88.4.719
  97. Gnanasegaran G, Buscombe JR, O’Rourke E, Caplin ME, Purfield D, Hilson AJW. Bremsstrahlung imaging after intra-arterial 90Y lanreotide radionuclide therapy for carcinoid liver metastases. Nucl Med Commun 2005;26(3):284–5.
  98. Luo J, Rao P, Zimmer M, Polis M, Mistretta M, Spies S. Imaging technique in estimating lung shunting of yttrium-90 microspheres. Med Phys 2005;32:1913.
  99. Minarik D, Sjogreen Gleisner K, Ljungberg M. Evaluation of quantitative 90Y bremsstrahlung SPECT based on patient studies. J Nucl Med 2009;50(2):378.
  100. Strigari L., Sciuto R., Rea S., Carpanese L., Pizzi G., Soriani A., Iaccarino G., Benassi M., Ettorre G. M., Maini C. L., Efficacy and Toxicity Related to Treatment of Hepatocellular Carcinoma with 90Y-SIR Spheres: Radiobiologic Considerations, 10.2967/jnumed.110.075861
  101. Schneider D. W., Heitner T., Alicke B., Light D. R., McLean K., Satozawa N., Parry G., Yoo J., Lewis J. S., Parry R., In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor-Bearing Nude Mice, 10.2967/jnumed.108.055608
  102. Lövqvist A, Humm JL, Sheikh A, Finn RD, Koziorowski J, Ruan S, et al. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. J Nucl Med 2001;42(8):1281–7.
  103. Garmestani Kayhan, Milenic Diane E, Plascjak Paul S, Brechbiel Martin W, A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin™, 10.1016/s0969-8051(02)00322-0
  104. Wei Lihui, Zhang Xiuli, Gallazzi Fabio, Miao Yubin, Jin Xiaofang, Brechbiel Martin W., Xu Heng, Clifford Thomas, Welch Michael J., Lewis Jason S., Quinn Thomas P., Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A″-Re(Arg11)CCMSH, 10.1016/j.nucmedbio.2009.01.007
  105. Helisch Andreas, F�rster GregorJ., Reber Helmut, Buchholz Hans-Georg, Arnold Rudolf, G�ke Burkhard, Weber MatthiasM., Wiedenmann Bertram, Pauwels Stanislas, Haus Ulrike, Bouterfa Hakim, Bartenstein Peter, Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours, 10.1007/s00259-004-1561-6
  106. Förster Gregor J., Engelbach Martin, Brockmann Jörg, Reber Helmut, Buchholz Hans-Georg, Mäcke Helmut R., Rösch Frank, Herzog Hans, Bartenstein Peter, Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide, 10.1007/s002590100628
  107. Reubi Jean Claude, Schär Jean-Claude, Waser Beatrice, Wenger Sandra, Heppeler Axel, Schmitt Jörg S., Mäcke Helmut R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use, 10.1007/s002590050034
  108. de Jong Marion, Bakker Willem H., Krenning Eric P., Breeman Wout A. P., van der Pluijm Marcel E., Bernard Bert F., Visser Theo J., Jermann Eduard, Béhé Martin, Powell Pia, Mäcke Helmut R., Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA 0 , d -Phe 1 ,Tyr 3 ]octreotide, a promising somatostatin analogue for radionuclide therapy, 10.1007/s002590050064
  109. Jacobs S. A., Harrison A. M., Swerdlow S. H., Foon K. A., Avril N., Vidnovic N., Joyce J., DeMonaco N., McCarty K. S., Radioisotopic Localization of 90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma, 10.1007/s11307-008-0170-3